StockData
Phathom Pharmaceuticals, Inc. logo

Phathom Pharmaceuticals, Inc. (PHAT) stock

PHATNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 4/30
$5.30−0.20 (-3.64%)

Close on Nov 18, 2026Market cap $430.85MP/E –Yield –

Phathom Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Phathom Pharmaceuticals's free cash flow for the twelve months ending Sep 30, 2026 was -$21.04M. For fiscal 2025 it was -$167.00M. The highest annual figure on record is -$36.64M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$167.00M–
FY2024Dec 31, 2024-$266.91M–
FY2023Dec 31, 2023-$139.21M–
FY2022Dec 31, 2022-$147.57M–
FY2021Dec 31, 2021-$148.79M–
FY2020Dec 31, 2020-$70.73M–
FY2019Dec 31, 2019-$36.64M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.73M–
Q2 FY2026Jun 30, 2026-$1.97M–
Q1 FY2026Mar 31, 2026-$15.71M–
Q4 FY2025Dec 31, 2025-$5.09M–
Q3 FY2025Sep 30, 2025-$14.14M–
Q2 FY2025Jun 30, 2025-$62.83M–
Q1 FY2025Mar 31, 2025-$84.95M–
Q4 FY2024Dec 31, 2024-$63.46M–
Q3 FY2024Sep 30, 2024-$63.62M–
Q2 FY2024Jun 30, 2024-$70.77M–
Q1 FY2024Mar 31, 2024-$69.06M–
Q4 FY2023Dec 31, 2023-$44.27M–
Q3 FY2023Sep 30, 2023-$32.85M–
Q2 FY2023Jun 30, 2023-$22.21M–
Q1 FY2023Mar 31, 2023-$39.88M–
Q4 FY2022Dec 31, 2022-$41.45M–
Q3 FY2022Sep 30, 2022-$35.15M–
Q2 FY2022Jun 30, 2022-$26.14M–
Q1 FY2022Mar 31, 2022-$44.82M–
Q4 FY2021Dec 31, 2021-$41.36M–
Q3 FY2021Sep 30, 2021-$29.08M–
Q2 FY2021Jun 30, 2021-$28.41M–
Q1 FY2021Mar 31, 2021-$49.93M–
Q4 FY2020Dec 31, 2020-$28.32M–
Q3 FY2020Sep 30, 2020-$20.91M–
Q2 FY2020Jun 30, 2020-$9.40M–
Q1 FY2020Mar 31, 2020-$12.09M–
Q4 FY2019Dec 31, 2019-$23.49M–

More Phathom Pharmaceuticals figures

See a number that looks wrong?